Status: Recruiting
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
The purpose of this study is to compare the efficacy of zipalertinib versus placebo in participants with early stage resected non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor mutation (EGFRmt).
Participants needed: 360
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Taiho Oncology, Inc.Updated: Oct 13, 2026Locations: 253
Eligibility criteria
Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamou... [+9]
Is currently receiving an investigational drug in a clinical trial or participat... [+15]